仅MRI检出的病灶:对比增强乳腺X线摄影引导活检能否作为替代方法——初步临床发现
回顾性分析2021年12月至2023年6月26例女性27个仅MRI检出乳腺病灶的CEM引导立体定向真空辅助活检,活检成功率93.1%(27/29),恶性9个(33.3%),活检阳性预测值33.3%,中位操作时间14分钟,显著短于同机构MRI引导活检(P<0.001)。作者认为CEM引导活检是可行、安全的替代方法,且无需预先CEM成像即可准确操作。
要点
- 仅MRI检出病灶行CEM引导活检成功率93.1%(27/29),恶性检出率33.3%(9/27)。
- CEM引导活检中位时间14分钟,较同机构MRI引导活检显著缩短(P<0.001),短24分钟。
- 无需预先CEM成像,直接以CEM定位像同时显示并定位病灶,中位定位像2幅。
核心结论
- CEM引导活检对仅MRI检出的强化病灶是可行、安全的替代方法,且较MRI引导活检更快。
- 无需预先CEM成像即可准确完成CEM引导活检。
研究设计与样本
- 回顾性分析,纳入2021年12月至2023年6月仅MRI检出乳腺病灶的CEM引导活检病例。
- 初始28例患者29个病灶,排除2例后共26例女性27个病灶,平均年龄44.96岁。
- 记录患者人口学、乳腺密度、病灶大小、CEM背景实质强化、病灶定位、操作时长及定位像数量。
- 早期7例患者在活检前接受CEM成像,后续病例以CEM定位像同时显示病灶并定位。
关键影像表现/征象
- 病灶大小4.5至41 mm,2个为肿块,其余为非肿块强化。
- 组织病理学检出9个恶性(33.3%,9/27),其中浸润癌55.6%(5/9)、导管原位癌44.4%(4/9)。
- 良性病变占66.7%,其中高危病变占22.2%。
- 活检成功率为93.1%(27/29),轻微并发症7例(25.9%,7/27),主要为小血肿,血管迷走神经反应1例(3.7%,1/27)。
- 中位定位像数量为2幅,有无预先CEM成像的病例间无显著差异(P=0.8)。
诊断标准与关键数值
- 活检阳性预测值为33.3%。
- CEM引导活检中位操作时间14分钟,较同机构MRI引导活检显著缩短(P<0.001),短24分钟。
- 患者体位以直立位为主(88.9%),进针方式以水平进针为主(92.6%)。
临床应用与阅片要点
- 对仅MRI检出的强化病灶,可考虑CEM引导立体定向真空辅助活检作为替代方法。
- 操作时可直接利用CEM定位像同时显示并定位病灶,无需预先CEM成像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to analyze our initial findings regarding CEM-guided stereotactic vacuum-assisted biopsy for MRI-only detected lesions and compare biopsy times by MRI-guided biopsy.
MATERIALS AND METHODS: In this retrospective analysis, CEM-guided biopsies of MRI-only detected breast lesions from December 2021 to June 2023were included. Patient demographics, breast density, lesion size, background parenchymal enhancement on CEM, lesion positioning, procedure duration, and number of scout views were documented. Initially, seven patients had CEM imaging before biopsy; for later cases, CEM scout views were used for simultaneous lesion depiction and targeting.
RESULTS: Two cases were excluded from the initial 28 patients with 29 lesions resulting in a total of 27 lesions in 26 women (mean age:44.96 years). Lesion sizes ranged from 4.5 to 41 mm, with two as masses and the remaining as non-mass enhancements. Histopathological results identified nine malignancies (33.3 %, 9/27), including invasive cancers (55.6 %, 5/9) and DCIS (44.4 %, 4/9). The biopsy PPV rate was 33.3 %. Benign lesions comprised 66.7 %, with 22.2 % high-risk lesions. The biopsy success rate was 93.1 % (27/29), and minor complications occurred in seven cases (25.9 %, 7/27), mainly small hematomas and one vasovagal reaction (3.7 %, 1/27). Median number of scout views required was 2, with no significant differences between cases with or without prior CEM (P = 0.8). Median duration time for biopsy was 14 min, significantly shorter than MRI-guided bx at the same institution (P < 0.001) by 24 min with predominantly upright positioning of the patient (88.9 %) and horizontal approach of the needle (92.6 %).
CONCLUSION: This study showed that CEM-guided biopsy is a feasible and safe alternative method and a faster solution for MRI-only detected enhancing lesions and can be accurately performed without the need for prior CEM imaging.
引用
- Aribal E, Guldogan N, Seker ME, et al. MRI only detected lesions: Can contrast enhanced mammography guided biopsy be an alternative method: Initial clinical findings. Eur J Radiol. 2024. PMID: 38364588. doi:10.1016/j.ejrad.2024.111373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。